These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 1948128)
1. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study. Westin J Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128 [TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996 [TBL] [Abstract][Full Text] [Related]
3. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study. Westin J; Cortelezzi A; Hjorth M; Rödjer S; Turesson I; Zador G Eur J Cancer; 1991; 27 Suppl 4():S45-8. PubMed ID: 1799477 [TBL] [Abstract][Full Text] [Related]
4. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. Westin J; Rödjer S; Turesson I; Cortelezzi A; Hjorth M; Zador G Br J Haematol; 1995 Mar; 89(3):561-8. PubMed ID: 7734355 [TBL] [Abstract][Full Text] [Related]
5. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094 [TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience. Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683 [TBL] [Abstract][Full Text] [Related]
7. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Wisløff F; Hjorth M; Kaasa S; Westin J Br J Haematol; 1996 Aug; 94(2):324-32. PubMed ID: 8759893 [TBL] [Abstract][Full Text] [Related]
8. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401 [TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957 [TBL] [Abstract][Full Text] [Related]
10. A review of the clinical studies of alpha-interferon in the management of multiple myeloma. Cooper MR Semin Oncol; 1991 Oct; 18(5 Suppl 7):18-29. PubMed ID: 1948125 [TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228 [TBL] [Abstract][Full Text] [Related]
12. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B]. Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946 [TBL] [Abstract][Full Text] [Related]
13. Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial. Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel RJ Invest New Drugs; 1987; 5 Suppl():S41-6. PubMed ID: 3597002 [TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple myeloma. San Miguel JF; Bladé Creixenti J; García-Sanz R Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392 [TBL] [Abstract][Full Text] [Related]
15. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202 [TBL] [Abstract][Full Text] [Related]
16. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
17. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Montuoro A; De Rosa L; De Blasio A; Pacilli L; Petti N; De Laurenzi A Br J Haematol; 1990 Nov; 76(3):365-8. PubMed ID: 2261347 [TBL] [Abstract][Full Text] [Related]
18. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476 [TBL] [Abstract][Full Text] [Related]
19. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden. Björkholm M Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480 [No Abstract] [Full Text] [Related]
20. Interferons in the treatment of multiple myeloma. Cooper MR; Welander CE Cancer; 1987 Feb; 59(3 Suppl):594-600. PubMed ID: 3802025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]